	SECURIT	IES AND EXCHANGE COMMI WASHINGTON, D.C. 20549	SSION						
		FORM 8-K							
		CURRENT REPORT Under Section 13 or 15(d) of							
		the Securities Exchange Act of 1934							
	D	ate of Report (Date of earliest event reported): January 23, 2014							
ResMed Inc. (Exact Name of Registrant as Specified in Charter)									
	Delaware (State or Other Jurisdiction of Incorporation)	001-15317 (Commission File Number)	98-0152841 (I.R.S. Employer Identification No.)						
		9001 Spectrum Center Blvd. San Diego, California 92123 (Address of Principal Executive Offices)							
		(858) 836-5000 (Registrant's telephone number, including area code)							
CI.									
	** *	ntended to simultaneously satisfy the filing obligation of the regi	strant under any of the following provisions:						
	Written communications pursuant to Rule 425 under	· · · · · · · · · · · · · · · · · · ·							
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)								

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 $Pre-commencement\ communications\ pursuant\ to\ Rule\ 13e-4(c)\ under\ the\ Exchange\ Act\ (17\ CFR\ 240.13e-4(c))$

Item 2.02. Disclosure of Results of Operations and Financial Condition.

On January 23, 2014 we issued the press release attached as Exhibit 99.1. It is incorporated into this report by reference. The press release describes the results of our operations for the quarter ended December 31, 2013.

Item 8.01. Other Events.

On January 23, 2014, we announced that our board of directors declared a cash dividend of US \$0.25 per share of outstanding common stock. The dividend will be payable on March 19, 2014, with a record date of February 19, 2014. We will pay the dividend in US currency to holders of our common stock trading on the New York Stock Exchange (NYSE). We will pay the dividend to holders of CHESS Depositary Instruments (CDIs) trading on the Australian Securities Exchange (ASX) at an equivalent amount in Australian currency, based on the exchange rate on February 19, 2014, and reflecting the 10:1 ratio between CDIs and NYSE shares. Because the two exchanges have different settlement and transfer procedures, the ex-dividend periods before the record date will be different for common stock and for CDIs. The ex-dividend date will be February 13, 2014 for CDI holders and February 15, 2014 for common stock holders. As a result of these differences, we have received a waiver from the ASX's settlement operating rules, which will allow us to defer processing conversions between its common stock and CDI registers from February 13, 2014 through February 19, 2014, inclusive.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits: Description of Document

99.1 Press Release dated January 23, 2014 regarding results of operations

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: January 23, 2014 RESMED INC. (registrant)

By: /s/ Brett Sandercock
Name: Brett Sandercock
Its: Chief Financial Officer

3

EXHIBIT INDEX

Exhibits: Description of Document

99.1 Press Release dated January 23, 2014 regarding results of operations



RESMED INC. ANNOUNCES RECORD FINANCIAL RESULTS FOR THE QUARTER ENDED AND SIX MONTHS ENDED DEC. 31, 2013

SAN DIEGO, California, Jan. 23, 2014—ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended Dec. 31, 2013. Revenue for the quarter ended Dec. 31, 2013 was \$384.3 million, a 2 percent increase (a 1 percent increase on a constant currency basis) over the quarter ended Dec. 31, 2012. For the quarter ended Dec. 31, 2013, net income was \$86.6 million, an increase of 11 percent compared to the quarter ended Dec. 31, 2012. Diluted earnings per share for the quarter ended Dec. 31, 2013 were \$0.60, an increase of 13 percent compared to the quarter ended Dec. 31, 2012.

SG&A expenses were \$111.7 million for the quarter ended Dec. 31, 2013, an increase of 4 percent (a 5 percent increase on a constant currency basis) over the quarter ended Dec. 31, 2012. SG&A costs were 29.1 percent of revenue in the quarter ended Dec. 31, 2013, compared to 28.6 percent in the quarter ended Dec. 31, 2012.

R&D expenses were \$29.5 million for the quarter ended Dec. 31, 2013, or 7.7 percent of revenue. R&D expenses decreased by 3 percent (a 5 percent increase on a constant currency basis) compared to the quarter ended Dec. 31, 2012. R&D expenses were favorably impacted by the depreciation of the Australian dollar against the U.S. dollar.

The company amortized acquired intangibles of \$2.5 million (\$1.9 million, net of tax) during the quarter ended Dec. 31, 2013. Stock-based compensation costs incurred during the quarter ended Dec. 31, 2013 of \$10.7 million (\$7.2 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and our employee stock purchase plan.

For the six months ended Dec. 31, 2013, revenue was \$742.0 million, an increase of 4 percent over the six months ended Dec. 31, 2012 (a 3 percent increase on a constant currency basis). For the six months ended Dec. 31, 2013, net income was \$167.6 million, an increase of 12 percent compared to the six months ended Dec. 31, 2012. Diluted earnings per share for the six months ended Dec. 31, 2013 were \$1.15 per diluted share, an increase of 13 percent compared to the six months ended Dec. 31, 2012.

In the second quarter of fiscal 2014, revenue outside the Americas was \$177.7 million, an increase of 8 percent over the prior year's quarter. In constant currency terms, revenue outside the Americas increased by 5 percent. Revenue in the Americas decreased by 2 percent compared to the prior year's quarter, to \$206.6 million. Operating profit for the December quarter grew to \$105.0 million, cash flow from operations was \$84.2 million, while gross margin expanded to 64.7 percent, all demonstrating robust operating performance. During the quarter, the company also repurchased 1.5 million shares at a cost of \$74.0 million as part of its ongoing capital management program.

Mick Farrell, ResMed's chief executive officer, commented, "While we are disappointed with the U.S. numbers, the two key issues, as we have previously noted, are market restructuring due to competitive bidding and increased competitor activity. Having said that, competitive bidding's impact on volume in the U.S. market is beginning to moderate, and we are partnering with our U.S. customers to position for the growth that we see ahead. It's important to note that we have a rich pipeline of products scheduled for introduction, and we remain optimistic about future growth in the U.S. market.

Highlighting an example of the company's new product pipeline, Farrell said, "Earlier this month in the U.S., we released our new AirFitTM P10 nasal pillows system, which is an ultra-light, ultra-quiet mask that has only three parts, including a new soft and stable QuickFitTM headgear and a new vent technology called QuietAirTM. The AirFit P10 is 50 percent quieter and 50 percent lighter than its predecessor, diffusing air with minimal disturbance to patients or their bed partners. In short, this is an exceptional mask, patient reviews have been strongly positive, and there are two more new masks behind it, scheduled to launch this fiscal year.

"During the second quarter, the Health Surveillance Agency approved our StellarTM ventilator for sale in Brazil. And we are on track to launch our next generation respiratory care ventilator platform in Europe in fiscal year 2014, with other markets to follow. We expect these launches and others from our pipeline to drive further growth in our global markets," he said.

"During this fiscal quarter, we benefitted from our broad global diversification with solid growth from our European teams and in our emerging market countries. Our German homecare and dealer businesses performed well in the quarter, and sales were strong in the U.K., Switzerland, and in European countries where we do not have direct subsidiaries. We are pleased with our global operational performance, which allowed us to expand gross margins, and grow earnings at double-digit rates this quarter," Farrell continued.

"Opportunities for growth remain in sleep, respiratory care, and cardiorespiratory markets in all geographies. We continue to focus on improving quality of life for patients who suffer from sleep-disordered breathing and respiratory insufficiency, including chronic obstructive pulmonary disease. Our team has the mission of preventing disease progression, improving outcomes, and reducing the cost of managing some of the most costly chronic diseases in the global healthcare system, including cardiovascular disease."

The ResMed board of directors has today declared a quarterly dividend of \$0.25 per share, which will have a record date of Feb. 19, 2014, and be payable on March 19, 2014. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange (NYSE). Holders of Chess Depositary Instruments (CDIs) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. Because the two exchanges have different settlement and transfer procedures, the ex-dividend periods before the record date will be different for common stock and for CDIs. The ex-dividend date will be Feb. 13, 2014 for CDI holders and Feb. 15, 2014 for common stock holders. As a result of these differences, ResMed has requested a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from Feb. 13, 2014 through Feb. 19, 2014, inclusive.

About ResMed

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

ResMed will host a conference call at 1:30 p.m. U.S. Pacific Time today to discuss these quarterly results. Individuals wishing to access the conference call may do so via ResMed's website at www.resmed.com or by dialing 847-585-4405 (domestic) or +1 847-585-4405 (international) and entering conference passcode no. 36303553. Please allow extra time prior to the call to visit the website and download the streaming media player (Windows Media Player) required to listen to the internet broadcast. The online archive of the broadcast will be available approximately 30 minutes after the live call and will be available for two weeks. A telephone replay of the conference call is available by dialing 630-652-3042 (domestic) and +1 630-652-3042 (international) and entering conference I.D. No. 36303553.

For Investors: Further information can be obtained by contacting David Pendarvis at ResMed Inc., San Diego, at (858) 836-5983; Brett Sandercock at ResMed Limited, Sydney, at (+612) 8884-2090; or by visiting the company's multilingual website at www.resmed.com.

For News Media: Contact Gretchen Griswold, director of Global Corporate Communications at (858) 836-6789.

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the company's future revenue, earnings or expenses, new product development and new markets for the company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the company files with the U.S. Securities & Exchange Commission. Those reports are available on the company's website.

RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In US\$ thousands, except per share data)

	Three Months Ended Dec. 31,		Six Months Ended Dec. 31,	
	2013	2012	2013	2012
Net revenue	\$384,341	\$376,537	\$742,003	\$716,269
Cost of sales	135,582	143,825	265,263	274,909
Gross profit	248,759	232,712	476,740	441,360
Operating expenses:				·
Selling, general and administrative	111,748	107,815	213,071	206,118
Research and development	29,537	30,326	56,900	57,546
Amortization of acquired intangible assets	2,454	2,501	4,866	5,138
Total operating expenses	143,739	140,642	274,837	268,802
Income from operations	105,020	92,070	201,903	172,558
Other income (expenses), net:				
Interest income (expense), net	6,752	8,498	13,166	16,970
Other, net	(2,311)	(2,168)	(3,539)	(227)
Total other income (expenses), net	4,441	6,330	9,627	16,743
Income before income taxes	109,461	98,400	211,530	189,301
Income taxes	22,825	20,458	43,964	40,094
Net income	\$ 86,636	\$ 77,942	\$167,566	\$149,207
Basic earnings per share	\$ 0.61	\$ 0.54	\$ 1.18	\$ 1.04
Diluted earnings per share	\$ 0.60	\$ 0.53	\$ 1.15	\$ 1.02
Basic shares outstanding	142,202	143,214	142,103	142,931
Diluted shares outstanding	145,335	146,689	145,412	146,382

RESMED INC AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited - In US\$ thousands)

ASSTES Current assets: 397.675 \$8.76.048 Accounts receivable, net 30.627 318.349 Inventories 178.077 145.847 Prepayments, deferred income taxes and other current assets 156.4132 1.048.048 Property, plant and equipment, net 414.344 411.433 Goodwill 290.45 274.829 Other intangibles 46,702 49.639 Obeferred income taxes and other non-current assets 30.36 25.971 Total anon-current assets 781.456 761.822 Total assets 5.2345.88 \$2.10.722 Total assets 5.6235 60.688 Account graph be 5.6235 60.688 Account graph be 5.6235 60.688 Accounts payable 5.6235 60.688 Accounts payable 11.946 137.64 Deferred income taxes 12.23 30.090 Income taxes payable 11.92 40.02 Non-current liabilities 10.274 8.95 Deferred income taxes <th></th> <th>Dec. 31, 2013</th> <th>June 30, 2013</th>		Dec. 31, 2013	June 30, 2013
Gas and cash equivalents \$72,0% \$87,0% Accounts receivable, net 318,349 Inventories 178,07 145,847 Prepayments, deferred income taxes and other current assets 111,753 100,005 Total current assets 1,564,132 1,448,849 Property, plant and equipment, net 41,413 11,133 Goodwill 90,005 274,829 Other intangibles 46,702 49,639 Deferred income taxes and other non-current assets 30,365 25,917 Total non-current assets 30,365 25,107 Total non-current assets 87,145 61,832 Total current assets 56,235 60,888 Total non-current assets 56,235 60,888 Accured expenses 56,235 60,888 Accurred expenses 141,946 137,674 Deferred income taxes 74 62,235 Current profit of long-term debt 18 30,001 Total current liabilities 10,274 9,895 Deferred income taxes 10,274	ASSETS		
Accounts receivable, nef 301,627 138.349 Inventories 178,077 145,847 Prepayments, deferred income taxes and other current assets 156,4132 1,448,849 Property, plant and equipment, net 414,344 411,343 Goodwill 290,045 274,829 Other intangibles 46,020 29,537 Deferred income taxes and other non-current assets 30,365 25,971 Total assets 781,856 76,1872 Total assets 52,245,88 32,002 Total assets 56,235 60,688 Account payable 56,235 60,688 Accounts payable 12,23 30,009 Deferred revenu 24,648 34,953 Deferred income taxes 741 62,72 Current portion of long-term debt 18 30,001 Total current liabilities 741 62,72 Deferred income taxes 14,94 18,93 Deferred revenue 11,92 19,93 Deferred revenue 12,04 8,95	Current assets:		
Inventories 18,077 148,847 Prepayment defered income taxes and other current assets 11,153 108,608 Total current assets 15,64,132 1,448,489 Property, plant and equipment, net 414,344 411,433 Goodwill 29,045 274,829 Other intangibles 46,702 49,639 Defered income taxes and other non-current assets 78,145 76,1872 Total non-current assets 78,145 76,1872 Total assets 2,345,588 \$2,210,721 Total assets 52,355,888 \$2,210,721 Total current assets \$2,345,588 \$2,210,722 Total assets \$2,345,588 \$2,210,722 Total assets \$2,345,588 \$2,210,722 Total assets \$2,345,588 \$2,210,722 Recerved expanses \$14,946 \$13,764 Accured expanses \$14,949 \$13,764 Deferred revenue \$14,943 \$13,644 Consecurent protion of long-term debt \$1,949 \$1,949 Deferred revenue \$1,949 </td <td>Cash and cash equivalents</td> <td>\$ 972,675</td> <td></td>	Cash and cash equivalents	\$ 972,675	
Prepayments, deferred income taxes and other current assets 111,733 108,065 Total current assets 1,564,132 1,448,489 Property, plant and equipment, net 414,34 414,33 Goodwill 290,045 274,829 Other intangibles 30,365 25,971 Total non-current assets 30,365 25,971 Total assets 2345,588 \$2,107,212 Income taxes and other non-current assets 2345,588 \$2,107,212 Total assets \$2,345,588 \$2,107,212 Income taxes and other non-current assets \$2,345,588 \$2,107,212 Total assets \$2,345,588 \$2,107,212 Income taxes \$2,345,588 \$2,107,212 Income taxes \$2,345,588 \$2,107,212 Income taxes \$2,345,588 \$2,107,212 Poffered reconsects \$2,345,588 \$2,107,212 Income taxes \$6,688 \$6,888 Accumed politic field field from taxes \$1,104 \$3,764 Poffered reconsect taxes \$1,223 \$3,000 Non-cu			
Total current assets 1,564,132 1,448,484 Proptry, plant and equipment, net 414,344 411,433 Goodwill 290,45 274,829 Other intangibles 46,702 49,639 Deferred income taxes and other non-current assets 781,455 76,1872 Total non-current assets 781,455 76,1872 Total sets 52,345,588 \$2,210,721 LIMITIES AND STOCKHOLDERS' EQUITY Urrent liabilities 56,235 60,688 Accured expense 161,966 137,674 Deferred revenue 42,648 44,933 Income taxes payable 24,248 30,001 Deferred income taxes 741 627 Current portion of long-term debt 242,811 574,049 Non-current liabilities 10,274 9,895 Deferred revenue 14,193 11,928 Deferred revenue 14,193 11,928 Deferred revenue 14,194 19,895 Deferred revenue 14,193 19,289 Deferred revenue			
Property, plant and equipment, net 414,344 411,433 Goodwill 290,045 274,829 Obther intagibles 46,702 49,639 Deferred income taxes and other non-current assets 30,365 25,971 Total assets \$2,345,588 \$2,210,721 LABILITIES AND STOCKHOLDER'S EQUITY Current liabilities: Caccounts payable 56,235 60,688 Account expenses 141,946 137,674 Deferred revenue 42,648 44,953 Income taxes payable 1223 30,090 Deferred income taxes 741 62.7 Current protino of long-tem debt 18 300,117 Total current liabilities 242,811 574,049 Non-current liabilities 10,274 9,895 Deferred revenue 14,193 11,928 Income taxes payable 3,564 3,564 Non-current protino of long-term debt 3,564 3,564 Income taxes 4,675 3,564 Non-current portion of long-term debt<	Prepayments, deferred income taxes and other current assets	111,753	108,605
Goodwilf 290,045 274,829 Other intangibles 46,702 49,639 Deferred income taxes and other non-current assets 30,365 25,971 Total non-current assets 781,456 761,872 Total assets 2,345,588 2,210,721 LABILITIES AND STOCKHOLDERS' EQUITY Current liabilities 8 56,235 60,688 Accunuts payable 56,235 60,688 Accunuts payable 56,235 60,688 Accunet spease 141,946 137,674 Deferred revenue 42,688 44,953 Income taxes payable 74 627 Current portion of long-term debt 18 30,017 Total current liabilities 242,811 574,494 Poferred income taxes 10,274 9,895 Deferred revenue 14,193 11,928 Deferred revenue 44,353 1,692 Deferred revenue 43,574 769 Deferred revenue 435,794 769 Total non-current liabilities <td>Total current assets</td> <td>_1,564,132</td> <td>1,448,849</td>	Total current assets	_1,564,132	1,448,849
Other intangibles 46,702 49,639 Defered income taxes and other non-current assets 30,365 25,971 Total non-current assets 781,456 761,872 Total assets 23,45,588 \$2,210,721 LINIBITIES AND STOCKHOLDER'S EQUITY Current liabilities: Accounts payable 56,235 60,688 Accounts payable 141,946 137,674 Deferred revenue 42,648 44,953 Deferred income taxes 741 627 Current portion of long-term debt 18 30,017 Total current liabilities 242,811 574,049 Non-current liabilities 10,274 9,895 Deferred revenue 11,928 9,895 Deferred revenue 14,193 11,928 Income taxes payable 3,564 3,564 Non-current portion of long-term debt 435,794 769 Deferred revenue 435,794 769 Income taxes payable 3,564 3,564 Non-current portion of long-ter	Property, plant and equipment, net	414,344	411,433
Deferred income taxes and other non-current assets 30,365 75,71 Total non-current assets 781,456 761,872 Total assets \$2,345,888 \$2,210,721 LABILITIES AND STOCKHOLDERS' EQUITY Urage in a special possibilities Accounts payable \$6,235 60,688 Accurued expenses 141,946 137,674 Deferred revenue 42,648 44,953 Income taxes payable 1,223 30,000 Deferred income taxes 74 627 Current portion of long-term debt 18 300,017 Total current liabilities 242,811 574,049 Deferred income taxes 10,274 9,895 Deferred revenue 10,274 9,895 Deferred income taxes 10,274 9,895 Deferred income taxes 10,274 9,895 Deferred revenue 3,564 3,564 Income taxes payable 3,564 3,564 Income taxes payable 3,564 3,564 Total incon-current portion of long-term debt	Goodwill	290,045	274,829
Total non-current assets 781,456 761,872 Total assets \$ 2,345,588 \$ 2,210,721 LABLITITES AND STOCKHOLDERS' EQUITY Current liabilities: \$ 56,235 60,688 Accounts payable 141,946 137,674 Deferred revene 44,648 44,953 Deferred income taxes 741 627 Current portion of long-term debt 18 300,017 Total current liabilities 242,811 574,049 Non-current liabilities 10,274 9,895 Deferred revenue 14,193 11,924 Deferred revenue 14,193 11,924 Income taxes payable 3,564 3,564 Non-current liabilities 3,564 3,564 Pofferred revenue 435,794 7,696 Non-current liabilities 3,564 3,564 Total non-current liabilities 2,516 6,696 Total liabilities 3,564 3,564 3,564 Non-current liabilities 5,602,502 5,602 5,602 5,602 <td>Other intangibles</td> <td>46,702</td> <td>49,639</td>	Other intangibles	46,702	49,639
Total assets \$ 2,345,588 \$ 2,10,721 LABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable 56,235 60,688 Accuted expenses 141,946 137,674 Deferred revenue 42,648 44,953 Income taxes payable 741 627 Current portion of long-tern debt 18 300,017 Total current liabilities 242,811 574,049 Non-current liabilities 10,274 9,895 Deferred income taxes 10,274 9,895 Income taxes payable 3,564 3,564 Non-current portion of long-tern debt 3,564 3,564 Non-current portion of long-tern debt 3,564 3,564 Non-current liabilities 463,825 26,155 Total liabilities 3,564 3,564 Non-current portion of long-tern debt 3,564 3,564 Non-current liabilities 56 60,025 Total liabilities 56 56 56	Deferred income taxes and other non-current assets	30,365	25,971
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: 66,688 Accounts payable 56,235 60,688 Accounts payable 141,946 137,674 Deferred revenue 42,648 44,953 Income taxes payable 741 627 Current portion of long-term debt 18 300,017 Total current liabilities 242,811 574,049 Non-current liabilities: 10,274 9,895 Deferred income taxes 10,274 9,895 Deferred revenue 14,193 11,928 Income taxes payable 3,564 3,564 Non-current portion of long-term debt 3,564 3,564 Total non-current growth of long-term debt 435,794 769 Total liabilities 706,636 600,205 STOCKHOLDERS' EQUITY: 443,894 40,682 26,156 Common stock 566 568 568 Additional paid-in capital 1,065,326 1,025,044 Retained earnings 1,073,083 1,576,641	Total non-current assets	781,456	761,872
Current liabilities: 60,688 60,609	Total assets	\$ 2,345,588	\$ 2,210,721
Accounts payable 56,235 60,688 Accrued expenses 141,946 137,674 Deferred revenue 42,648 44,953 Income taxes payable 1,223 30,000 Deferred income taxes 741 627 Curnent portion of long-tern debt 18 300,017 Total current liabilities 242,811 574,049 Non-current liabilities 10,274 9,895 Deferred revenue 14,193 11,928 Income taxes payable 3,564 3,564 Non-current portion of long-tern debt 435,794 769 Total non-current liabilities 463,825 26,156 Total inon-current liabilities 566 568 Total non-current liabilities 566 568 STOCKHOLDER'S EQUITY: 560 568 Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock 1,178,940 (1,88,845) To	LIABILITIES AND STOCKHOLDERS' EQUITY		
Accrued expenses 141,946 137,674 Deferred revenue 42,648 44,953 Income taxes payable 1,223 30,090 Deferred income taxes 741 627 Current portion of long-term debt 18 300,017 Total current liabilities	Current liabilities:		
Deferred revenue 42,648 44,953 Income taxes payable 1,223 30,000 Deferred income taxes 741 627 Current portion of long-term debt 38 300,017 Total current liabilities 242,811 574,049 Non-current liabilities 10,274 9,895 Deferred revenue 14,193 11,928 Income taxes payable 3,564 3,564 Non-current portion of long-term debt 3,564 3,564 Non-current liabilities 463,825 26,156 Total labilities 706,636 600,205 STOCKHOLDERS' EQUITY: 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock 6,1178,945 (1,938,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,605,352 1,610,516	Accounts payable	56,235	60,688
Income taxes payable 1,223 30,090 Deferred income taxes 741 627 Current portion of long-term debt 18 300,017 Total current liabilities 242,811 574,049 Non-current liabilities: 10,274 9,895 Deferred income taxes 11,274 9,895 Deferred revenue 14,193 11,928 Income taxes payable 3,564 3,564 Non-current portion of long-term debt 435,794 769 Total non-current liabilities 463,825 26,156 Total liabilities 706,636 600,205 STOCKHOLDERS' EQUITY: 566 568 Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,851 Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,610,516 1,610,516		141,946	137,674
Deferred income taxes 741 627 Current portion of long-term debt 18 300,017 Total current liabilities 242,811 574,049 Non-current liabilities: 9895 Deferred income taxes 10,274 9,895 Deferred revenue 10,274 9,895 Income taxes payable 3,564 3,564 Non-current portion of long-term debt 435,794 769 Total non-current liabilities 463,825 26,156 Total liabilities 706,636 600,205 STOCKHOLDERS' EQUITY: 566 568 Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Deferred revenue		44,953
Current portion of long-term debt 18 300,017 Total current liabilities 242,811 574,049 Non-current liabilities: 10,274 9,895 Deferred revenue 11,274 9,895 Deferred revenue 3,648 3,564 Income taxes payable 3,564 3,564 Non-current portion of long-term debt 435,794 769 Total non-current liabilities 463,825 26,156 Total liabilities 706,636 600,205 STOCKHOLDERS' EQUITY: 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock 1,178,946 (1,183,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516			
Total current liabilities 242,811 574,049 Non-current liabilities: 574,049 574,049 Deferred income taxes 10,274 9,895 Deferred revenue 14,193 11,928 Income taxes payable 3,564 3,564 Non-current portion of long-term debt 435,794 769 Total non-current liabilities 706,636 600,205 Total liabilities 566 568 STOCKHOLDERS' EQUITY: 566 568 Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516			
Non-current liabilities: Image: Content of the content o	Current portion of long-term debt	18	300,017
Deferred income taxes 10,274 9,895 Deferred revenue 14,193 11,928 Income taxes payable 3,564 3,564 Non-current portion of long-term debt 435,794 769 Total non-current liabilities 463,825 26,156 Total liabilities 706,636 600,205 STOCKHOLDERS' EQUITY: Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,983,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Total current liabilities	242,811	574,049
Deferred revenue 14,193 11,928 Income taxes payable 3,564 3,564 Non-current portion of long-term debt 435,794 769 Total non-current liabilities 463,825 26,156 Total liabilities 706,636 600,205 STOCKHOLDERS' EQUITY: Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Non-current liabilities:		
Income taxes payable 3,564 3,564 Non-current portion of long-term debt 435,794 769 Total non-current liabilities 463,825 26,156 Total liabilities 706,636 600,205 STOCKHOLDERS' EQUITY: S 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Deferred income taxes	10,274	9,895
Non-current portion of long-term debt 435,794 769 Total non-current liabilities 463,825 26,156 Total liabilities 706,636 600,205 STOCKHOLDERS' EQUITY: Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Deferred revenue	14,193	11,928
Total non-current liabilities 463,825 26,156 Total liabilities 706,636 600,205 STOCKHOLDERS' EQUITY: Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Income taxes payable	3,564	3,564
Total liabilities 706,636 600,205 STOCKHOLDERS' EQUITY: Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Non-current portion of long-term debt	435,794	769
STOCKHOLDERS' EQUITY: Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Total non-current liabilities	463,825	26,156
Common stock 566 568 Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,983,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Total liabilities	706,636	600,205
Additional paid-in capital 1,065,326 1,025,064 Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	STOCKHOLDERS' EQUITY:		
Retained earnings 1,673,083 1,576,641 Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Common stock	566	568
Treasury stock (1,178,946) (1,083,845) Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Additional paid-in capital	1,065,326	1,025,064
Accumulated other comprehensive income 78,923 92,088 Total stockholders' equity 1,638,952 1,610,516	Retained earnings	1,673,083	1,576,641
Total stockholders' equity 1,638,952 1,610,516			
	Accumulated other comprehensive income	78,923	92,088
Total liabilities and stockholders' equity \$\frac{1}{2},345,588\$ \$\frac{1}{2},210,721\$	Total stockholders' equity	_1,638,952	1,610,516
	Total liabilities and stockholders' equity	<u>\$ 2,345,588</u>	\$ 2,210,721